Search

Displaying results 5001 - 5010 of 10000 in total
  1. Drug

    Snail, unspecified

    go.drugbank.com/drugs/DB14245
    ApprovedInvestigational

    Snail, unspecified is an animal extract used in some OTC (over-the-counter) products. It is not an approved drug.

  2. Drug

    Benidipine

    go.drugbank.com/drugs/DB09231
    Investigational

    [A31948] It was originated in Japan by Kyowa Hakko, it is submitted for FDA approval and it is currently available in some Asian countries like India and Japan.[L1385, L1386] … It is a synthetic dihydropyridine derivative that has anti-hypertensive and anti-anginal actions.

  3. Drug

    Levilimab

    go.drugbank.com/drugs/DB16387
    Investigational

    Levilimab is under investigation in clinical trial NCT04227366 (Study of the Efficacy and Safety of BCD-089 in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis).

  4. Drug

    Talampanel

    go.drugbank.com/drugs/DB04982
    Investigational

    Talampanel is a substance that is being studied in the treatment of brain tumors and other brain disorders, such as epilepsy and Parkinson disease. It is a type of AMPA receptor antagonist.

  5. Drug

    Sapacitabine

    go.drugbank.com/drugs/DB06365
    Investigational

  6. Drug

    D-JNKI-1

    go.drugbank.com/drugs/DB05660
    Investigational

    A synthetic, cell permeable peptide that blocks the MAPK-JNK signal pathway; has potential therapeutic value for long-term protection of both the morphological integrity and physiological function of the organ of Corti during times of ox...

  7. Drug

    Bexotegrast

    go.drugbank.com/drugs/DB16515
    Investigational

    In addition, the compound is also currently in Phase 2a trials (NCT04565249) for the treatment of COVID-19 related acute respiratory distress syndrome[L31713]. … The compound was granted orphan drug designation by the US FDA in August 2018 for treatment of IPF, and Pliant Therapeutics recently raised $100 million in Series C financing to support further clinical

  8. Drug

    IR208

    go.drugbank.com/drugs/DB05106
    Investigational

    It contains three peptides (BV5S2, BV6S5 and BV13S1) expressed by T-Cells in over 90% of MS patients. IR208 is currently undergoing Phase II studies in a 200-patient trial. … IR208 is a synthetic T-Cell receptor peptide vaccine developed by Immune Response Corporation.

  9. Drug

    JB991

    go.drugbank.com/drugs/DB05081
    Experimental

    In addition a closely related cyclopentenone prostaglandin analogue has been shown to exert marked anti-inflammatory effect in vivo in an animal model. The drug will be applied topically on the skin. … The drug exerts marked antiproliferative and pro-apoptotic effect in human keratinocytes and fibroblasts in vitro.

  10. Drug

    VPM4001

    go.drugbank.com/drugs/DB05089
    Experimental

    VPM4001 is an allogeneic vaccine for treatment of prostate carcinoma. … It consists of irradiated human LNCaP cells that have been genetically modified to permanently secrete interferon-γ and interleukin-2 (LNCaP/IL-2/IFN-γ).